[1]
Martin, L., Alibhai, S., Komisarenko, M., Timilshina, N. and Finelli, A. 2018. Identification of subgroups of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone plus prednisone at low- vs. high-risk of radiographic progression: An analysis of COU-AA-302. Canadian Urological Association Journal. 13, 6 (Nov. 2018). DOI:https://doi.org/10.5489/cuaj.5586.